R&D Reuters Pharma Europe 2024 – Peter Stenico Pioneering access to biosimilars is crucial for strengthening health equity by providing affordable, life-changing therapies to patients worldwide.
Partner Content Partner Content World Biosimilars Market will surge at 27%+ CAGR up to 2025 Biosimilars Market will surpass USD 69 billion by 2025
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.